Inhibikase Therapeutics Inc (IKT) - Total Liabilities
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has total liabilities worth $6.70 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Inhibikase Therapeutics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See IKT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Inhibikase Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Automotive Systems Inc
F:RYV
|
Germany | €432.84 Million |
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
Spain | €38.85 Million |
|
Endava plc
F:2Y5
|
Germany | €362.92 Million |
|
Quartzsea Acquisition Corporati
NASDAQ:QSEA
|
USA | $4.23 Million |
|
Lam Soon (Thailand) Public Company Limited
BK:LST
|
Thailand | ฿3.00 Billion |
|
Roots Corp
TO:ROOT
|
Canada | CA$159.59 Million |
|
Kangnam Jevisco Co Ltd
KO:000860
|
Korea | ₩265.49 Billion |
|
China Silver Group Limited
F:2CS
|
Germany | €662.84 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Inhibikase Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Inhibikase Therapeutics Inc (IKT) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inhibikase Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Inhibikase Therapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.73 Million | +5.80% |
| 2023-12-31 | $3.53 Million | -9.54% |
| 2022-12-31 | $3.90 Million | -3.79% |
| 2021-12-31 | $4.05 Million | -18.88% |
| 2020-12-31 | $5.00 Million | +10.38% |
| 2019-12-31 | $4.53 Million | +24.94% |
| 2018-12-31 | $3.62 Million | +109.97% |
| 2017-12-31 | $1.73 Million | +13.97% |
| 2016-12-31 | $1.51 Million | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more